114 related articles for article (PubMed ID: 38723157)
21. Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population.
Adehin A; Bolaji OO; Maggo S; Kennedy MA
Drug Metab Pers Ther; 2017 Mar; 32(1):39-47. PubMed ID: 28231062
[TBL] [Abstract][Full Text] [Related]
22. Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis.
Sun WX; Chen YH; Liu ZZ; Xie JJ; Wang W; Du YP; Chen Y; Shen XL; He XF; Wu LX; Wei W; Zhang L
Mol Genet Genomics; 2015 Apr; 290(2):709-25. PubMed ID: 25472037
[TBL] [Abstract][Full Text] [Related]
23. Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone.
Kubbara A; Amundson WH; Herman A; Lee AM; Bishop JR; Kim HJ
Heliyon; 2023 Aug; 9(8):e18573. PubMed ID: 37560683
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.
Liao D; Liu Z; Zhang Y; Liu N; Yao D; Cao L; Chen Y; Fu Y; Yang N; Xiang D
Front Pharmacol; 2020; 11():664. PubMed ID: 32457635
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. Effects of
Muñoz A; López-Samanes Á; Aguilar-Navarro M; Varillas-Delgado D; Rivilla-García J; Moreno-Pérez V; Del Coso J
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32823594
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of
Bozkurt I; Gözler T; Yüksel I; Ulucan K; Tarhan KN
Balkan J Med Genet; 2023 Jul; 26(1):35-42. PubMed ID: 37576788
[TBL] [Abstract][Full Text] [Related]
28. Current evidence on the relationship between three polymorphisms in the CYP1A2 gene and the risk of cancer.
Zhenzhen L; Xianghua L; Ning S; Zhan G; Chuanchuan R; Jie L
Eur J Cancer Prev; 2013 Nov; 22(6):607-19. PubMed ID: 23462460
[TBL] [Abstract][Full Text] [Related]
29. Association between the CYP1A2 rs762551 Polymorphism and Bladder Cancer Susceptibility: a Meta-Analysis Based on Case-Control Studies.
Zeng Y; Jiang HY; Wei L; Xu WD; Wang YJ; Wang YD; Liu C
Asian Pac J Cancer Prev; 2015; 16(16):7249-54. PubMed ID: 26514519
[TBL] [Abstract][Full Text] [Related]
30. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients.
Kootstra-Ros JE; Smallegoor W; van der Weide J
Ann Clin Biochem; 2005 May; 42(Pt 3):216-9. PubMed ID: 15949157
[TBL] [Abstract][Full Text] [Related]
31. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
32. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
Cottin V; Koschel D; Günther A; Albera C; Azuma A; Sköld CM; Tomassetti S; Hormel P; Stauffer JL; Strombom I; Kirchgaessler KU; Maher TM
ERJ Open Res; 2018 Oct; 4(4):. PubMed ID: 30364407
[TBL] [Abstract][Full Text] [Related]
33. A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study.
Sköld CM; Janson C; Elf ÅK; Fiaschi M; Wiklund K; Persson HL
Eur Clin Respir J; 2016; 3():32035. PubMed ID: 27435431
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
35. Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking.
Yoshida K; Osawa K; Kasahara M; Miyaishi A; Nakanishi K; Hayamizu S; Osawa Y; Tsutou A; Tabuchi Y; Shimada E; Tanaka K; Yamamoto M; Takahashi J
Asian Pac J Cancer Prev; 2007; 8(3):438-44. PubMed ID: 18159984
[TBL] [Abstract][Full Text] [Related]
36. The effect of CYP1A2 genotype on the ergogenic properties of caffeine during resistance exercise: a randomized, double-blind, placebo-controlled, crossover study.
Rahimi R
Ir J Med Sci; 2019 Feb; 188(1):337-345. PubMed ID: 29532291
[TBL] [Abstract][Full Text] [Related]
37. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; Endo N; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2003 Mar; 55(3):321-4. PubMed ID: 12630986
[TBL] [Abstract][Full Text] [Related]
38. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin.
Härtter S; Korhonen T; Lundgren S; Rane A; Tolonen A; Turpeinen M; Laine K
Basic Clin Pharmacol Toxicol; 2006 Oct; 99(4):300-4. PubMed ID: 17040215
[TBL] [Abstract][Full Text] [Related]
39. [Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].
Xue S; Lu H; Tang L; Fang J; Shi L; Li J; Yu Y; Zhou Q; Xue S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):50-55. PubMed ID: 32148231
[TBL] [Abstract][Full Text] [Related]
40. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
